Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

25
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
25
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

71
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
71
Angina IV: Management01:26

Angina IV: Management

22
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
22
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association Between Interventional Cardiologist Practice Characteristics, Coronary Artery Bypass Grafting Use, and Clinical Outcomes.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026
Same author

Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study.

Circulation·2026
Same author

Pace and Ablate or Pace Then Ablate: Defining the Risk of Concomitant AV Node Ablation and Pacemaker Implantation Using a Probability Based Approach.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Focal and Diffuse Coronary Artery Disease Patterns and Placebo-Controlled Angina Relief With Percutaneous Coronary Intervention: ORBITA-2.

Journal of the American College of Cardiology·2026
Same author

Robust fine-grained echocardiographic view classification with supervised contrastive learning.

Medical image analysis·2026
Same author

Association Between Age and PCI Effectiveness in Stable CAD: Secondary Analysis of ORBITA-2.

Journal of the American College of Cardiology·2026

Related Experiment Video

Updated: Sep 8, 2025

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

8.1K

Revascularization in stable coronary artery disease.

Rasha K Al-Lamee1,2, Michael Foley1,2, Christopher A Rajkumar1,2

  • 1National Heart and Lung Institute, Imperial College London, UK.

BMJ (Clinical Research Ed.)
|June 13, 2022
PubMed
Summary

For stable coronary artery disease (CAD), revascularization like bypass surgery may not prevent heart attacks or death as previously thought. Current evidence suggests a re-evaluation of these invasive procedures for stable CAD patients is needed.

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.7K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

Related Experiment Videos

Last Updated: Sep 8, 2025

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

8.1K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.7K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Trials

Background:

  • Stable coronary artery disease (CAD) management traditionally involves medications to prevent myocardial infarction and death.
  • Revascularization procedures, such as coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), were historically assumed to prevent adverse events and alleviate symptoms in stable CAD.
  • Recent randomized controlled trials (RCTs) challenge these long-held assumptions regarding the benefits of revascularization.

Purpose of the Study:

  • To critically evaluate the current evidence base for revascularization in stable coronary artery disease (CAD) in light of recent trial data.
  • To examine the role of revascularization in high-risk patient groups for myocardial infarction and death.
  • To identify uncertainties, research gaps, and potential communication issues in clinical practice.

Main Methods:

  • Review and synthesis of evidence from recent randomized controlled trials, including the ISCHEMIA trial.
  • Analysis of contemporary practice guidelines and recommendations for stable CAD.
  • Focus on patient subgroups with high risk of adverse cardiovascular events.

Main Results:

  • Recent RCTs, such as the ISCHEMIA trial, provide evidence that challenges the routine use of revascularization for stable CAD.
  • The benefits of revascularization in preventing myocardial infarction and death in stable CAD patients are less certain than previously assumed.
  • Specific patient groups may still benefit from revascularization, but clear indications require further investigation.

Conclusions:

  • The evidence supporting revascularization for stable coronary artery disease (CAD) requires re-evaluation, particularly in light of the ISCHEMIA trial.
  • Contemporary management should carefully consider the risks and benefits of revascularization versus optimal medical therapy.
  • Further research is needed to clarify the role of revascularization in specific high-risk populations and to improve doctor-patient communication regarding treatment decisions.